ReviewCancers2020
Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3-Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia.Phytotherapy research : PTR · 2026Article
- Integrative multi-transcriptomics and network pharmacology reveal natural therapeutics as anti-cancer agents targeting AURKA for ovarian cancer treatment.Journal, genetic engineering & biotechnology · 2026Article
- Article
- Inhibition of the PI3K signaling pathway in cancer cells by Agrimonia eupatoria L. ethanolic extract: identification of tricoumaroyl spermidine as a potential PI3K inhibitor.BMC complementary medicine and therapies · 2026Article
- Bioactive Plant-Derived Compounds as Novel Perspectives in Oral Cancer Alternative Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The potential of blackcurrant, fig, and grape leaf extracts in the development of new preparations for overcoming antibiotic resistance and enhancing the efficacy of chemotherapeutic agents.BMC complementary medicine and therapies · 2025Article
- Unveiling the link between chronic inflammation and cancer.Metabolism open · 2025Review
- Exploring the application of herbal photosensitizers in antimicrobial photodynamic therapy against3 Biotech · 2025Review
- Natural Anticancer Drugs: Efficacy, Safety, and Future Challenges.Current medicinal chemistry · 2025Review
- Natural compounds in ovarian cancer: mechanistic insights and therapeutic potential.Frontiers in pharmacology · 2025Review
- Nanoparticle-mediated delivery of herbal-derived natural products to modulate immunosenescence-induced drug resistance in cancer therapy: a comprehensive review.Frontiers in oncology · 2025Review
- Oligandrin fromHeliyon · 2024Article
- Comparative Anti-Cancer and Anti-Inflammatory Activities of Essential Oils from the Bark and Flower ofFoods (Basel, Switzerland) · 2024Article
- Advances in the role of resveratrol and its mechanism of action in common gynecological tumors.Frontiers in pharmacology · 2024Review
- The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.Frontiers in immunology · 2024Review
- Synergistic Antitumor Effect ofMolecules (Basel, Switzerland) · 2023Article
- Rise of the natural red pigment 'prodigiosin' as an immunomodulator in cancer.Cancer cell international · 2022Review
- Antitumor Potential of Immunomodulatory Natural Products.Marine drugs · 2022Review
- Recent advances in aptamer applications for analytical biochemistry.Analytical biochemistry · 2022Article
- LncRNAFrontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-related deaths are approaching 10 million each year. Survival statistics for some cancers, such as ovarian cancer, have remained unchanged for decades, with women diagnosed at stage III or IV having over 80% chance of a lethal cancer recurrence after standard first-line treatment (reductive surgery and chemotherapy). New treatments and adjunct therapies are needed. In ovarian cancer, as in other cancers, the immune response, particularly cytotoxic (CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.